Limits...
The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.

Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, Maciejewski A, Zebracka-Gala J, Lange D, Oczko-Wojciechowska M, Handkiewicz-Junak D, Jarzab B - PLoS ONE (2015)

Bottom Line: BRAF V600E mutation was found in 54.5%.BRAF status was associated neither with relapse nor with disease-free survival (DFS) (p=0.76).Nodal status, extrathyroidal invasion and tumour size significantly influenced DFS.

View Article: PubMed Central - PubMed

Affiliation: The Oncologic and Reconstructive Surgery Clinic, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.

ABSTRACT

Introduction: The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. The presence of BRAF mutation, the most frequent molecular event in PTC, seems to be a good candidate. However, there is still lack of randomised trials and its significance has been proved by retrospective analyses, involving a large group of patients. The question arises whether this factor is useful in smaller populations, characterised for specialised centres. Thus, the aim of the study was to evaluate the use of BRAF mutation as a potential predictive marker in PTC patients.

Material: 233 PTC subjects treated between 2004-2006, were retrospectively analysed. Stage pT1 was diagnosed in 64.8% patients and lymph node metastases in 30.9%. Median follow-up was 7.5 years. BRAFV600E mutation was assessed postoperatively in all cases.

Results: BRAF V600E mutation was found in 54.5%. It was more frequent in patients > 45 years (p=0.0001), and associated with larger tumour size (p=0.004). Patients with tumours <= 10 mm were over-represented among BRAF negative population (p=0.03). No association between BRAF mutation and other clinicopathological factors was observed. BRAF status was associated neither with relapse nor with disease-free survival (DFS) (p=0.76). Nodal status, extrathyroidal invasion and tumour size significantly influenced DFS.

Conclusion: The risk of PTC recurrence is mainly related to the presence of lymph node metastases and extrathyroidal invasion, whereas no impact of BRAF V600E mutation has been demonstrated.

No MeSH data available.


Related in: MedlinePlus

The presence of BRAF mutation did not increase the risk of cancer relapse (A). However, known histopathological factors, such as lymph node involvement (B) and thyroid capsule infiltration (C) significantly influenced disease-free survival.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4503446&req=5

pone.0132821.g003: The presence of BRAF mutation did not increase the risk of cancer relapse (A). However, known histopathological factors, such as lymph node involvement (B) and thyroid capsule infiltration (C) significantly influenced disease-free survival.

Mentions: BRAF status was associated neither with the cancer relapse nor with the time to relapse. Within the BRAF(+) group 7 cancer recurrences were noted (5.5%), including 6 local relapses and 1 distant metastases, whereas in the BRAF(-) group 5 cancer recurrences (4.7%) were reported, including 3 local relapses and 2 cases of local relapse with concurrent metastatic disease. There was no difference in DFS between BRAF(+) and BRAF(-) groups (Fig 3; p = 0.76).


The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.

Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, Maciejewski A, Zebracka-Gala J, Lange D, Oczko-Wojciechowska M, Handkiewicz-Junak D, Jarzab B - PLoS ONE (2015)

The presence of BRAF mutation did not increase the risk of cancer relapse (A). However, known histopathological factors, such as lymph node involvement (B) and thyroid capsule infiltration (C) significantly influenced disease-free survival.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4503446&req=5

pone.0132821.g003: The presence of BRAF mutation did not increase the risk of cancer relapse (A). However, known histopathological factors, such as lymph node involvement (B) and thyroid capsule infiltration (C) significantly influenced disease-free survival.
Mentions: BRAF status was associated neither with the cancer relapse nor with the time to relapse. Within the BRAF(+) group 7 cancer recurrences were noted (5.5%), including 6 local relapses and 1 distant metastases, whereas in the BRAF(-) group 5 cancer recurrences (4.7%) were reported, including 3 local relapses and 2 cases of local relapse with concurrent metastatic disease. There was no difference in DFS between BRAF(+) and BRAF(-) groups (Fig 3; p = 0.76).

Bottom Line: BRAF V600E mutation was found in 54.5%.BRAF status was associated neither with relapse nor with disease-free survival (DFS) (p=0.76).Nodal status, extrathyroidal invasion and tumour size significantly influenced DFS.

View Article: PubMed Central - PubMed

Affiliation: The Oncologic and Reconstructive Surgery Clinic, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.

ABSTRACT

Introduction: The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. The presence of BRAF mutation, the most frequent molecular event in PTC, seems to be a good candidate. However, there is still lack of randomised trials and its significance has been proved by retrospective analyses, involving a large group of patients. The question arises whether this factor is useful in smaller populations, characterised for specialised centres. Thus, the aim of the study was to evaluate the use of BRAF mutation as a potential predictive marker in PTC patients.

Material: 233 PTC subjects treated between 2004-2006, were retrospectively analysed. Stage pT1 was diagnosed in 64.8% patients and lymph node metastases in 30.9%. Median follow-up was 7.5 years. BRAFV600E mutation was assessed postoperatively in all cases.

Results: BRAF V600E mutation was found in 54.5%. It was more frequent in patients > 45 years (p=0.0001), and associated with larger tumour size (p=0.004). Patients with tumours <= 10 mm were over-represented among BRAF negative population (p=0.03). No association between BRAF mutation and other clinicopathological factors was observed. BRAF status was associated neither with relapse nor with disease-free survival (DFS) (p=0.76). Nodal status, extrathyroidal invasion and tumour size significantly influenced DFS.

Conclusion: The risk of PTC recurrence is mainly related to the presence of lymph node metastases and extrathyroidal invasion, whereas no impact of BRAF V600E mutation has been demonstrated.

No MeSH data available.


Related in: MedlinePlus